The novel peptide DR4penA attenuates the bleomycin‐ and paraquat‐induced pulmonary fibrosis by suppressing the TGF ‐ β /Smad signaling pathway
The FASEB Journal · 2023
DOI: 10.1096/fj.202301363r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Dan Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Materia Medica and Research Unit of Peptide Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Pulmonary Fibrosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Pulmonary fibrosis (PF), which is caused by continuous alveolar epithelial cell injury and abnormal repair, is referred to as a difficult disease of the lung system by the World Health Organization due to its rapid progression, poor prognosis, and high mortality rate. However, there is still a lack of ideal therapeutic strategies. The peptide DR8 (DHNNPQIR‐NH 2 ), which is derived from rapeseed, exerted antifibrotic activity in the lung, liver, and kidney in our previous studies. By studying the structure–activity relationship and rational design, we introduced an unnatural hydrophobic amino acid ( α ‐(4‐pentenyl)‐Ala) into DR8 and screened the novel peptide DR4penA (DHN α ‐(4‐pentenyl)‐APQIR‐NH 2 ), which had higher anti‐PF activity, higher antioxidant activity and a longer half‐life than DR8. Notably, DR4penA attenuated bleomycin‐ and paraquat‐induced PF, and the anti‐PF activity of DR4penA was equivalent to that of pirfenidone. Additionally, DR4penA suppressed the TGF‐ β /Smad pathway in TGF‐ β 1‐induced A549 cells and paraquat‐induced rats. This study demonstrates that the novel peptide DR4penA is a potential candidate compound for PF therapy, and its antifibrotic activity in different preclinical models of PF provides a theoretical basis for further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Materia Medica and Research Unit of Peptide Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Medical Imaging Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong, China.
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
- School of Biomedical Engineering, Shenzhen University Health Science Centre, Shenzhen University, Shenzhen, China.
- School of Pharmaceutical Sciences, Shenzhen University Health Science Centre, Shenzhen University, Shenzhen, China.
ORCID-Profile: Dan Wang, Bochuan Deng, Lu Cheng, Jieru Li, Xiaomin Guo, Jiao Zhang, Xiang Zhang, Ping Su, Guofeng Li, Xiaokang Miao, Wenle Yang, Junqiu Xie, Rui Wang
Förderung
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, D., Deng, B., Cheng, L., Li, J., Guo, X., Zhang, J., Zhang, X., Su, P., Li, G., Miao, X., Yang, W., Xie, J., & Wang, R. (2023). The novel peptide DR4penA attenuates the bleomycin‐ and paraquat‐induced pulmonary fibrosis by suppressing the TGF ‐ β /Smad signaling pathway. The FASEB Journal. https://doi.org/10.1096/fj.202301363r
Vancouver
Wang D, Deng B, Cheng L, Li J, Guo X, Zhang J, et al. The novel peptide DR4penA attenuates the bleomycin‐ and paraquat‐induced pulmonary fibrosis by suppressing the TGF ‐ β /Smad signaling pathway. The FASEB Journal. 2023. doi:10.1096/fj.202301363r
BibTeX
@article{Wang2023,
author = {Wang, Dan and Deng, Bochuan and Cheng, Lu and Li, Jieru and Guo, Xiaomin and Zhang, Jiao and Zhang, Xiang and Su, Ping and Li, Guofeng and Miao, Xiaokang and Yang, Wenle and Xie, Junqiu and Wang, Rui},
title = {The novel peptide DR4penA attenuates the bleomycin‐ and paraquat‐induced pulmonary fibrosis by suppressing the TGF ‐ β /Smad signaling pathway},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202301363r}
}
EUVIMED